eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | eosinophilic pneumonia |
| Comorbidity | C0004096|asthma |
| Sentences | 7 |
| PubMedID- 22901886 | Interpretation: mepolizumab is an effective and well tolerated treatment that reduces the risk of asthma exacerbations in patients with severe eosinophilic asthma. |
| PubMedID- 24734097 | Interpretation: mepolizumab is an effective and well tolerated treatment that reduces the risk of asthma exacerbations in patients with severe eosinophilic asthma. |
| PubMedID- 24148899 | Also, anti-il-5 antibody mesolizumab has shown efficacy in reducing asthma exacerbations in patients with severe eosinophilic asthma. |
| PubMedID- 25199060 | Mepolizumab, a humanized monoclonal antibody that binds to and inactivates interleukin-5, has been shown to reduce asthma exacerbations in patients with severe eosinophilic asthma. |
| PubMedID- 20358030 | Crofton et al.8 have classified this disease entity into five groups: simple pulmonary eosinophilia or löffler's syndrome, prolonged pulmonary eosinophilia, pulmonary eosinophilia with asthma, topical eosinophilia, and pulmonary eosinophilia with polyarteritis nodosa. |
| PubMedID- 26504401 | Mepolizumab was demonstrated to significantly reduce the number of asthma exacerbations in patients with severe eosinophilic asthma compared with placebo. |
| PubMedID- 25124713 | Pfascin-betagal mice might represent a mouse model to study pathophysiological mechanisms proceeding in the subgroup of asthmatics with non-eosinophilic asthma that respond to inhaled steroids. |
Page: 1